Torus Lu, MA

Torus Lu specializes in supporting counsel and experts working on complex litigation and government investigations in the life sciences sector. He leads teams that leverage large, complex data sets to analyze liability, damages, and class certification issues in antitrust, securities, mass tort, and reimbursement dispute matters. These data sets include pharmaceutical sales and chargeback, market sales, Medicaid and Medicare, financial, and claims. He has assisted counsel and testifying experts in all phases of litigation, including government investigations, discovery, settlement negotiations, and trial.

MA, Economics, University of Georgia

BA, Economics, University of Georgia

• In In re Generic Pharmaceuticals Pricing Antitrust Litigation and related government investigations, provided consulting support on behalf of a large generic pharmaceutical manufacturer in connection with allegations that it conspired to fix prices or allocate markets.
• In In LIBOR-Based Financial Instruments Antitrust Litigation—The OTC Action, supported the testifying expert on behalf of a class of over-the-counter plaintiffs against the global banks that set US Dollar LIBOR. Analyzed impact and damages and led team managing interest rate swap transaction data.
• Supported advisory opinions and analyses of the expert in resolution of over 80,000 Zantac and generic ranitidine claims brought against GSK.
• In In Sake TN, LLC and Seanache Homes, Inc. v. Patrick Moss, IRA Innovations, LLC, Mary M. Wester, supported testifying expert regarding economic issues related to class certification and class-wide damages methodology in response to allegations that defendants made usurious loans and charged interest rates that exceeded the maximum effective rate allowed under Tennessee law.
• Provided consulting support for work involving a large multinational pharmaceutical company. Developed a user-friendly tool to inform optimal bidding strategy in pharmaceutical and biosimilars tenders based on auction theory.
• In In re Teva Securities Litigation, supported the testifying expert on antitrust issues associated with alleged misrepresentations regarding the sources of Teva’s profits and the competitiveness of markets for generic drugs.